

WITH A SIMPLE TEST

What is Proclarix?

NON-INVASIVE
Diagnosis without the risk, pain or costs of tissue biopsies

Proclarix combines clinically proven¹⁻³ blood biomarker assays with an easy to use clinical decision support software to support physicians striving to deliver next-generation prostate cancer diagnosis to their patients. Proclarix increases diagnostic accuracy compared to %fPSA alone and therefore makes it easier to decide whether a biopsy or mpMRI is useful or not.

Laboratory



PSA + Proclarix-Assays:
Same blood sample is reused for reflex test

Physician



Proclarix CDS & Report:
Risk score for significance of prostate cancer


The ready-to-use **Proclarix Assays** measure THBS1 and CTSD from the same blood sample as PSA. Any diagnostic laboratory can perform the assays on their existing infrastructure.

The **Proclarix Risk Calculator** is an easy-to-use software combining blood biomarkers results with patient age. The resulting **Proclarix Report** provides the risk score for clinically significant cancer.

PRECISE
Proclarix reliably identifies high-grade prostate cancer

ACCESSIBLE
Proclarix is easily performed at your local laboratory

CLARITY IS JUST




Proclarix is indicated in men with elevated total PSA (2.0-10.0 ng/ml), a digital rectal examination finding consistent with elevated prostate volume (≥ 35 ml) and not suspicious for cancer.

Proclarix safeguards your decision as to whether a biopsy, multiparametric MRI (mpMRI), or “watchful waiting” is the best option for your patient.


Proclarix Facts

- **90% sensitivity¹**: 9 out of 10 patients with clinically significant, GS ≥ 7 , prostate cancer are detected
- **43% specificity¹**: 43% of the biopsies can be avoided adding Proclarix to the diagnostic procedure
- **95% NPV¹**: 19 out of 20 men are correctly ruled out to have no or insignificant cancer
- Same serum sample used for Proclarix and PSA test
- Same day results
- Manual or automated processing
- CE-IVD marked

Scientific Evidence




Risk score correlation with aggressiveness of PCa detected on biopsy¹



- Proclarix can safely guide the use of mpMRI⁴
- Proclarix will help to resolve indeterminate mpMRI⁴

Advantages Proclarix brings to your practice:

- The number of biopsies needed to reliably detect clinically significant prostate cancer is reduced by 37 %.
- Avoiding unnecessary biopsies reduces costs and saves time in patient management.
- Your patient gets clarity faster and experiences less stress.



References

¹Klocker, H. et al. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. *BJU Compass* 2020 1(1), 15-20

²Endt K. et al. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. *PLoS ONE* 2017;12:e0181557-14

³Steuber T. et al. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies. *BJU Int* 2018. doi:10.1111/bju.14540

⁴Pye, H. et al. Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. *Journal of Clinical Oncology* 2020 38(6_suppl), 278-278

Clear answers on unclear PSA results

Proclarix

The new prostate cancer solution helping you better manage your patient's journey

Get clarity now and contact us:

Proteomedix
Wagistrasse 21
CH-8952 Schlieren
Tel. +41 44 733 40 90

contact@proteomedix.com



Elevated PSA?



Proclarix®

NEXT generation blood test for Prostate Cancer